Investigational drug · Phase 3
TQA3605
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Chronic Hepatitis b, Chronic Hepatitis B, HBV Infection With LLV.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
2 still active
All registered trials
4
Any phase or sponsor naming "TQA3605"
First trial start
2023
Dec 7, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TQA3605", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Hepatitis b
- Chronic Hepatitis B
- HBV Infection With LLV
Approved drugs for the same conditions: Hepatitis B · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "TQA3605" as an intervention, largest first.
- Clinical Trial of TQA3605 Tablet in Combination With Nucleos(t)Ide Analogues(NAs) Versus NAs Alone for the Treatment of Patients With Chronic Hepatitis B Virus Infection Who Have Undergone Treatment and Exhibit Low Viral Load or Poor ResponsePivotal-lookingNot yet recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT07797231 · 930 participants (planned) · Start Nov 2026 · Primary completion Sep 2028
Drug: TQA3605 tablets Placebo; TQA3605 tablets and 4 more · For: Chronic Hepatitis B
Sites: Hefei, China; Wuhu, China; Beijing, China · 76 sites in all
- Clinical Study of TQA3605 Tablets Combined With Nucleoside (Acid) Analogs (NAs) Drugs Compared With NAs Drugs in the Treatment of Chronic Hepatitis B Virus (HBV) InfectionPivotal-lookingCompleted
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT06644417 · 122 participants · Start Nov 14, 2024 · Primary completion Aug 25, 2025
Drug: TQA3605 tablets plus NAs; TQA3605 Placebo plus NAs · For: HBV Infection With LLV
Sites: Beijing, China; Fuzhou, China; Shenzhen, China · 19 sites in all
- A Clinical Study of TQA3605 Tablets Monotherapy or in Combination With Nucleoside (Acid) Analogues in Treatment Naive and Treated Patients With Chronic Hepatitis BActive, not recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT06150014 · 88 participants · Start Dec 7, 2023 · Primary completion Dec 2025
Drug: Placebo; TQA3605 tablets and 3 more · For: Chronic Hepatitis b
Sites: Chongqing, China; Xi'an, China · 3 sites in all
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT06990776 · 0 participants · Start Jul 9, 2025 · Primary completion Jul 17, 2025
Drug: TQA3605 tablets Placebo; TQA3605 Tablets and 1 more · For: Chronic Hepatitis B
Sites: Beijing, China; Chongqing, China; Fuzhou, China · 29 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Chronic Hepatitis b
- GST-HG141Phase 33 trials
Fujian Akeylink Biotechnology Co., Ltd. · Chronic Hepatitis b, Chronic Hepatitis B
- TAFPhase 33 trials
Gilead Sciences · HIV-1-infection, Chronic Hepatitis B
- HRS-5635Phase 32 trials
Fujian Shengdi Pharmaceutical Co., Ltd. · Chronic Hepatitis B, Nucleos(t)Ide Analogue-suppressed HBeAg-negative Patients With Chronic Hepatitis B
- Peg-IFN-αpegylated interferonPhase 26 trials
Brii Biosciences Limited · Chronic Hepatitis B, Chronic Hepatitis B Virus (HBV) Infection, Hepatitis B, Chronic
- TVAX-008Phase 24 trials
Grand Theravac Life Sciences (Nanjing) Co., Ltd. · Chronic Hepatitis B, HBV Infection, Chronic Hepatitis B Virus
- HT-101Phase 23 trials
Suzhou HepaThera Biotech Co., Ltd. · Chronic Hepatitis B, Chronic Hepatitis B Virus Infection
- HT-102Phase 23 trials
Suzhou HepaThera Biotech Co., Ltd. · Chronic Hepatitis B, Chronic Hepatitis B Virus Infection
- NAsNucleoside analogs, acidPhase 23 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chronic Hepatitis B, HBV Infection With LLV
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.